This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Generic Drug ETF Offering Portfolio Cure

2/12/16 12:47 PM EST
With biotech stocks getting smashed on the stock market and big pharma getting hammered on the presidential campaign trail, generic drug stocks look awfully appealing, said James Duffy, product manager at Van Eck Global. 'Generics will benefit from the ongoing push to lower healthcare costs,' said Duffy. 'Another good reason is the big push now into biosimilars, the generic forms of the big biotech drugs which we have been hearing so much about over the past 10 or 15 years.' Last month Van Eck introduced the Market Vectors Generic Drugs exchange traded fund (GNRX), the first ETF to target global manufacturers of generic drugs and biosimilars. Shares of the fund are down almost 9% since the fund’s January 13th launch. Duffy pointed out that according to the Generic Pharmaceutical Association, 88% of the drugs dispensed in the U.S. are generics. He added that spending on generics, as a percentage of drugs distributed globally, is expected to increase from 40% in 2013 to 46 percent in 2018. One of the benefits of the GNRX, in Duffy’s view is the international diversification of the fund. As of December 31st, 39% of the constituents in GNRX’s underlying index were domiciled in the United States, with India, Israel, South Korea and Japan, having the next largest country weightings, respectively.
Stocks in this video: GNRXTEVAMYLPRGO
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs